{"id":"W2552620919","doi":"10.1182/blood.v114.22.302.302","title":"Updated Results of Bortezomib-Naive Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Medicine; Tolerability; Proteasome inhibitor; Multiple myeloma; Internal medicine; Phases of clinical research; Refractory (planetary science); Adverse effect; Clinical endpoint; Pharmacology; Oncology; Gastroenterology; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002484543,0.0007210033,0.001735306,0.0004627652,0.0003540922,0.0008828343,0.0006351201,0.0007092739,0.002289039],"category_scores_gemma":[0.00203908,0.0003914165,0.001071653,0.0005639016,0.0002585509,0.0008353907,0.0004251794,0.001454681,0.0006153255],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006151974,"about_ca_system_score_gemma":0.000646381,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001423488,"about_ca_topic_score_gemma":0.001843137,"domain_scores_codex":[0.9988762,0.0004749604,0.00009222177,0.0001764992,0.0002276724,0.0001525721],"domain_scores_gemma":[0.9982637,0.0003827754,0.0005380266,0.0001624268,0.0001937526,0.0004594638],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3886917,0.01183978,0.3469838,0.001022972,0.004371887,0.0009630386,0.0009803312,0.00348303,0.06701272,0.0001978783,0.01051288,0.16394],"study_design_scores_gemma":[0.02497989,0.08824752,0.8646508,0.00005658179,0.003192264,0.001619549,0.0001766315,0.00164929,0.005562991,0.0001556713,0.009645144,0.0000635664],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889528,0.002407695,0.0003368301,0.0001674371,0.00003846462,0.0003789994,0.005838742,0.00005992897,0.001819169],"genre_scores_gemma":[0.9807288,0.0007133166,0.0007595882,0.0004069751,0.00007647608,0.000361402,0.01589465,0.00002773145,0.001031008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002484543,"threshold_uncertainty_score":0.01313967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04407682764474058,"score_gpt":0.3293003965449342,"score_spread":0.2852235689001936,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}